TransGenex Nanobiotech, Inc. (TGN), is a Florida-based nanobiotechnology company incorporated in 2004.

Our Mission is to discover, develop and commercialize nano-scale technologies for novel, cost-effective diagnostic and therapeutic agents against cancers and other inflammatory diseases.

Contact Us

Latest News

June 27, 2015

Transgenex Nanobiotech, Inc. chooses Dr. Chandresh Saraiya as its President

June 18, 2015

Florida Institute Funds Tampa-based TransGenex Nanobiotech, Inc.



The Florida Institute for the Commercialization of Public Research

October 14, 2014

Transgenex co-founder Dr. Subhra Mohapatra receives USF’s Excellence in Innovation Award.

USF Research News

September 16, 2014

TransGenex Receives $224,999in SBIR Phase-I Contract from National Cancer Institute to further develop and commercialize a biopsy-derived tumoroid platform for personalizing cancer treatment.

TransGenex Receives a second $224,999in SBIR Phase-I Contract from National Cancer Institute to develop new drugs targeting cancer stem cells.


Anti-Cancer Drug Discovery


Personalized Cancer Therapy
3D Tumor